Salvador Borromeo, MD
Cardiovascular Disease · Las Vegas, NVNPI 1669461919
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,250 of the $22,875 with a category attached, or 75.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 85.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $19,299 and has fallen 99.1% since, to $169 in 2025.
Across 133 payments — averaging $171.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
- Cvrx, Inc.$2K
- Abbott$541
- Smith+Nephew$302
- AstraZeneca$160
- Philips North America LLC$154
- plus $479 from 14 others
Across 2 payments — averaging $10,968 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$22K
What the payments were for
- Speaking & faculty fees$17,25075%
- Travel & lodging$1651%
- Food & beverage$5,34523%
- Education$1141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 60 | $19,586 |
| Cvrx, Inc. | 18 | $1,653 |
| Abbott | 5 | $541 |
| Smith+Nephew | 18 | $302 |
| AstraZeneca | 4 | $160 |
| Philips North America LLC | 6 | $154 |
| Boston Scientific | 3 | $78 |
| Acera Surgical, Inc. | 2 | $75 |
| Novo Nordisk | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Melinta Therapeutics, LLC | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| KCI USA, Inc. | 1 | $29 |
| Acell, Inc. | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Abiomed | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$17,653
- Barostim Neo System$1,112
- Confirm Rx$325
- Assurity Pacemaker$154
How this compares
$22,875 in reported general payments places this provider in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $31,943 |
| XareltoRivaroxaban | 27 | $30,108 |
| OzempicSemaglutide | 13 | $20,080 |
| Amiodarone Hcl | 25 | $1,451 |
| Atorvastatin Calcium | 88 | $1,047 |
| Metoprolol Succinate | 65 | $978 |
| Tamsulosin Hcl | 54 | $941 |
| Losartan Potassium | 78 | $899 |
| ClopidogrelClopidogrel Bisulfate | 53 | $836 |
| Pantoprazole Sodium | 47 | $836 |
| Nifedipine ErNifedipine | 21 | $814 |
| Levetiracetam | 18 | $619 |
| Levothyroxine Sodium | 57 | $613 |
| Risperidone | 28 | $584 |
| Amlodipine Besylate | 55 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $31,94331 claims |
| Johnson & JohnsonXarelto | $12 | $30,10827 claims |
| Novo NordiskOzempic | $48 | $20,08013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.